Las Vegas, September 7, 2021 (PRNewswire) – Alkame Holdings, Inc.
The company’s strategic debt has agreed with Blue City LLC to restructure four alternative notes held by Blue City. Notes, general $ 988,000 In principle, it also carries an estimated accumulated interest $ 350,000.00. Blue City has agreed to restructure the loan and cancel all accumulated interest and avoid future interest rates.
“This huge debt restructuring is combined with last week’s change $ 100,000 In debt b .01 dollars It has significantly reduced the repetitive impact on the company’s capital structure. Above all, the removal of future interest on these notes will be avoided $ 1.0 million It will pave the way for the protection of new lending institutions that will support the company’s growth in the coming months. As we look forward to a happy end to the year and 2022 and beyond, this is the next step to strengthen the balance of power, ”said Robert Eckle, CEO.
About Alkame Holdings, Inc.
Alcame Holdings is an publicly traded health and safety technology company focused on inpatient, innovative and environmentally friendly consumer products. The company’s fully-fledged branches produce patented water using patented technology to create a number of unique properties. The company has launched and acquired appropriate business assets, and followed a number of applications into a number of emerging business sectors such as consumer bottled water and RTD products, pet products, horticultural and agricultural applications, hand sanitizers for new and existing business platforms and much more. Water-based treatment solutions.
For more information, visit www.alkameholdingsinc.com.
Alkame Holdings, Investor Relations
Website www.alkameholdingsinc.com
Email [email protected]
Phone: 702-273-9714
Disclaimer / Safe Harbor: This newsletter contains forward-looking statements in the translation of the Safe Arbitration Amendment Act. The statements reflect the company’s current views on future events, including risks and mistrust. Among other things, these risks are expected to result in significant sales, non-compliance with the company’s timetable or performance requirements, the company’s liquidity, the company’s ability to obtain new contracts, the emergence of highly competitive competitors, and the impact of competitive prices. In light of these instability, future events mentioned in this release may not occur. These statements have not been reviewed by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
Source: Alkame Holdings, Inc.
Related links
http://www.alkameholdingsinc.com
.